BluePeak Advisors, Dallas, TX.
Beth Israel Deaconess Medical Center, Boston, MA.
J Manag Care Spec Pharm. 2021 Aug;27(8):1129-1135. doi: 10.18553/jmcp.2021.27.8.1129.
In response to a published national payer survey indicating striking needs for multistakeholder initiatives to increase biosimilar adoption, a focus workgroup meeting joining payers and providers was conducted in December 2019 in Boston, MA. Before the focus group meeting, a survey was sent to health care providers to collect perceptions about barriers to biosimilar adoption and gather input on best potential strategies for addressing these barriers. The focus group panel consisted of 5 managed care pharmacists and 3 physician experts in rheumatology, dermatology, and gastroenterology, representing large managed care organizations and health care systems in the Boston area. A clinical moderator facilitated discussions between the payers and providers regarding challenges to biosimilar adoption and potential collaborative strategies to overcome these barriers. The focus group participants identified hurdles to biosimilar adoption in 3 major areas: (1) the lack of confidence in biosimilar interchangeability and a need for education about biosimilars, (2) the lack of financial incentives to switch to biosimilars from the reference biologic product, and (3) administrative burdens that impair the prescription of biologics. Learning from their mutual experiences, the focus group participants formulated action plans to address these barriers. The top strategies recommended by the participants included advancing biosimilar education, facilitating administrative processes related to biosimilar prescriptions, and increasing provider reimbursement while reducing cost sharing to patients receiving biosimilars. The study reported on in this article was part of a continuing education program funded by an independent educational grant that was awarded by Sandoz Inc., a Novartis Division, to PRIME Education, LLC. The grantor had no role in the study design, execution, analysis, or reporting. The Academy of Managed Care Pharmacy (AMCP) received grant funding from PRIME to assist with participant recruitment and content review for the continuing education program. Bandekar, Cheifetz, Edgar, Helfgott, Hoye-Simek, Liu, and Smith received an honorarium from PRIME for serving as faculty for the continuing education program. Cheifetz has received research grants from Inform Diagnostics and consulting fees from AbbVie, Bacainn, BMS, Grifols, Janssen, Pfizer, Prometheus, Samsung, and Takeda unrelated to this work. Smith has received consulting fees from Boehringer-Ingelheim, has served as an investigator on industry-initiated trials for AbbVie and Pfizer, and has served as an investigator on investigator-initiated trials for Novartis and Regeneron. Carter, Fajardo, and Simone have nothing to disclose.
针对一项发表的全国医保调查表明，需要多方利益相关者采取行动来提高生物类似药的采用率，2019 年 12 月在马萨诸塞州波士顿举行了一次由医保方和医疗服务提供方参加的重点工作组会议。在重点小组会议之前，向医疗服务提供者发送了一项调查，以收集他们对采用生物类似药障碍的看法，并收集解决这些障碍的最佳潜在策略的意见。重点小组的成员由 5 名管理式医疗药剂师和 3 名风湿病、皮肤科和胃肠病学专家组成，代表了波士顿地区的大型管理式医疗组织和医疗保健系统。一名临床主持人促进了医保方和医疗服务提供者之间关于生物类似药采用挑战和潜在合作策略的讨论，以克服这些障碍。重点小组参与者确定了生物类似药采用的 3 个主要障碍领域：（1）对生物类似药可互换性的信心不足，需要教育生物类似药知识；（2）缺乏从参考生物制品转为生物类似药的经济激励措施；（3）行政负担阻碍了生物制剂的处方。重点小组参与者从相互经验中吸取了教训，制定了行动计划来解决这些障碍。参与者推荐的主要策略包括推进生物类似药教育，促进与生物类似药处方相关的行政流程，增加提供者的报销，同时降低接受生物类似药治疗的患者的自付费用。本文报道的研究是由 Sandoz Inc.（诺华公司的一个部门）授予 PRIME 教育公司的一项独立教育资助的继续教育计划的一部分。资助者在研究设计、执行、分析或报告方面没有任何作用。 Academy of Managed Care Pharmacy（AMCP）从 PRIME 获得赠款，以协助继续教育计划的参与者招募和内容审查。Bandekar、Cheifetz、Edgar、Helfgott、Hoye-Simek、Liu 和 Smith 因担任继续教育计划的教师而从 PRIME 获得酬金。Cheifetz 已从 Inform Diagnostics 获得研究资助，并从 AbbVie、Bacainn、BMS、Grifols、Janssen、Pfizer、Prometheus、Samsung 和 Takeda 获得与这项工作无关的咨询费。Smith 从 Boehringer-Ingelheim 获得咨询费，曾参与 AbbVie 和 Pfizer 的行业发起的试验，以及 Novartis 和 Regeneron 的试验。Carter、Fajardo 和 Simone 没有需要披露的内容。
